Wakamoto Pharmaceutical
4512
Smile Holdings
7084
T.O. Holdings
9812
Land
8918
GMO internet
4784
JP Stock MarketDetailed Quotes
2370 Medinet
- 36
- +1+2.86%
20min DelayTrading Feb 28 10:44 JST
9.53BMarket Cap-7.14P/E (Static)
36High35Low249.60KVolume36Open35Pre Close8.93MTurnover5752wk High0.10%Turnover Ratio264.73MShares3452wk Low-5.04EPS TTM8.79BFloat Cap13900Historical HighLossP/E (Static)244.22MShs Float33Historical Low-5.04EPS LYR2.86%Amplitude--Dividend TTM1.83P/B100Lot Size--Div YieldTTM
Medinet News
Medinet: Summary of Financial Results for the first quarter 2025
Medinet: Notice regarding the recording of non-operating income
Medinet: Notice regarding the death of an auditor and the appointment of an alternate auditor as an auditor
Medinet: Independent Officer Registration Form
Medinet: Notice regarding the recording of special profit (profit from sale of investment securities)
Medinet: Notice Concerning Election of Director Candidates and Audit & Supervisory Board Candidates
Medinet: Notice Concerning Decrease in Capital and Capital Reserve Amounts and Disposal of Surplus Funds
Medinet: Notice regarding the recording of non-operating income and extraordinary losses
Medinet: Summary of Financial Results 2024
Medinet: Explanatory materials on business plans and growth potential
Medinet: [Progress of disclosure matters] Decision to discontinue development of regenerative medicine products for the purpose of treating chronic heart failure
Medinet: Notice regarding mass exercise and completion of exercise of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third party allotment
Medinet: Strategic partnership agreement signed with AGC for cell therapy CDMO business
Medinet: Notice regarding the monthly exercise status of the 19th Stock Acquisition Rights (with exercise price amendment clause) through third-party allotment
Medinet: Announcements of individual stocks regarding the recognition of non-operating revenue.
Medinet: Overview of Q3 2024 financial results.
Medinet: Started manufacturing outsourcing for a new specified cell processed product ("S-DSC") related to hair regeneration.
Medinet: (Progress of disclosure matters) Taiwanese regulatory authorities have approved the provision of γδT cell therapy at new medical institutions (progress of licensing agreement with Medigen Biotechnology Corp.)
Medinet: Notice Concerning the Recording of Non-Operating Income and Non-Operating Expenses
Medinet: Summary of financial results for the 2nd quarter of 2024